Reimbursement and Health Economics
Reimbursement and Health Economics helps the founder or programme team complete a focused intervention on payer, health economics, procurement and payment route. Within Specialist Sector Support, it turns a broad or uncertain area of the venture into a concrete Bertie work product that can be reviewed, improved and reused. The task is intentionally discrete: it should produce a specific artefact, decision, evidence item or risk signal rather than general learning notes.
Complete a focused intervention that advances Reimbursement and Health Economics. The objective is to remove ambiguity around payer, health economics, procurement and payment route, give the founder a decision-ready output, and make it clear whether the venture should progress, repeat the task with stronger evidence, escalate to expert support, or move into a linked stage.
Bertie or a programme manager assigns Reimbursement and Health Economics when the venture needs a decision-ready output for this group. Typical triggers include group-gate reviews, evidence gaps identified by the co-pilot or founder request.
venture sector; domain assumptions; relevant regulation or evidence standard; product maturity; sector buyer map; specific context for payer, health economics, procurement and payment route.
The founder articulates why a health economics and reimbursement strategy is required at this precise stage of venture maturity. They define whether the objective is to secure NHS tariff coding, unlock private medical insurance coverage, or establish a direct business-to-business healthcare procurement route.
ObjectiveEstablishing a clear scope prevents wasting resources on irrelevant clinical or economic modelling for non-viable buyer segments. It ensures the venture focuses exclusively on the commercialisation pathway that matches its target clinical deployment and buyer profile, maximising speed to market.
What's expectedA documented scope charter outlining the target payment ecosystem, decision-maker personas, and the precise economic milestone required. The founder must explicitly state the core hypothesis regarding who pays, how much, and through which exact budget code or procurement mechanism.
Open action arrow_forwardConsultant stress-test · 5 questions- 1.What specific clinical pathway trigger or commercial milestone makes addressing reimbursement urgent right now?
- 2.Why have you chosen this specific payment mechanism over alternative commissioning pathways in your target health system?
- 3.How does this reimbursement objective align with your current clinical evidence generation plan?
- 4.What evidence do you have that the target buyer actually utilises the payment code you intend to target?
- 5.If this specific reimbursement route fails, what is the immediate secondary commercial fallback?
- A data-room asset titled Reimbursement and Health Economics
- A clear task output, updated venture DNA and recommended next action
- It should update the venture DNA with specific evidence or decisions about payer, health economics, procurement and payment route, create a visible milestone in the founder journey, and generate one or more recommended next tasks
Bertie co-pilot applies sector-specific criteria, flags regulatory or evidence gaps, prepares expert review briefs, and connects the venture to specialist tasks. For this task, it should focus on payer, health economics, procurement and payment route, prompt the founder for missing inputs, draft or improve the output, flag weak assumptions, and record the result back into the relevant data-room section.
A mentor or evaluator can review the output at the group gate. Programme managers can require an advisor checkpoint before Bertie moves the venture forward.